Latoya Grey, FNP-BC

Michal Bar-Natan, MD, is Associate Professor of Clinical Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City. Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute. Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.

Dr. Bashir Al Hussein is a Urologic Oncologist and Assistant Professor of Urology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He completed his urology residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a Society of Urologic Oncology (SUO) fellowship at Vanderbilt University Medical Center. He also holds a Master of Public Health in Epidemiology from Vanderbilt University and earned his medical degree from the University of Jordan in Amman.Dr. Al Hussein is a urologic cancer surgeon who specializes in the diagnosis and management of genitourinary malignancies, including prostate, kidney, bladder, testicular, and penile cancers. He provides comprehensive cancer care using both robotic and open surgical approaches, tailored to the complexity and stage of each patient’s disease. His expertise includes minimally invasive robotic procedures—such as radical prostatectomy, partial nephrectomy, and cystectomy—as well as complex open operations for advanced or anatomically challenging tumors.Dr. Al Hussein’s research focuses on applying epidemiologic methods to improve the quality of cancer care, with an emphasis on decision-making, survivorship, and health literacy. His work has been published in leading journals, including The Journal of the American Medical Association (JAMA), The New England Journal of Medicine, and JAMA Internal Medicine. He is a recipient of the American Urological Association Research Scholar Award and serves as Director of the Adult Urology Clinic within the Department of Urology at Weill Cornell Medicine.NewsMost Men With Low-Risk Prostate Cancers Now Forgo Immediate Surgeryhttps://www.usnews.com/news/health-news/articles/2023-04-04/most-men-with-low-risk-prostate-cancers-now-forgo-immediate-surgeryDecade-Long Study Offers Guidance on Treatments for Prostate Cancerhttps://www.usnews.com/news/health-news/articles/2024-01-24/decade-long-study-offers-guidance-on-treatments-for-prostate-cancerInsights into adverse effects may help guide prostate cancer treatment decision-makinghttps://www.healio.com/news/hematology-oncology/20240227/insights-into-adverse-effects-may-help-guide-prostate-cancer-treatment-decisionmakingComparing Side Effects of Prostate Cancer Treatmentshttps://newsinhealth.nih.gov/2024/04/comparing-side-effects-prostate-cancer-treatmentsMore U.S. Prostate Cancer Patients Choosing Active Surveillancehttps://www.newswise.com/articles/more-u-s-prostate-cancer-patients-choosing-active-surveillance2More Men Choose Active Surveillance for Prostate Cancerhttps://www.newsmax.com/health/health-news/prostate-cancer-low-risk/2023/04/05/id/1115105/More men with prostate cancer opting for active surveillancehttps://www.healio.com/news/hematology-oncology/20230403/more-men-with-prostate-cancer-opting-for-active-surveillancehttps://www.usatoday.com/story/news/health/2024/01/24/prostate-cancer-treatment-study/72336323007/10-year study evaluates prostate cancer treatments, side effectshttps://www.msn.com/en-us/health/other/10-year-study-evaluates-prostate-cancer-treatments-side-effects/ar-BB1hc5v7Understanding Functional Outcomes in Prostate Cancerhttps://www.medscape.com/s/viewarticle/understanding-functional-outcomes-prostate-cancer-2024a10001t2?src=rssTreatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancerhttps://www.physiciansweekly.com/treatment-adverse-events-vary-with-favorable-unfavorable-prognosis-in-prostate-cancer/Cory Booker didn’t go to the bathroom for 25 hours. Is that … OK?https://www.theguardian.com/wellness/2025/apr/03/how-long-without-peeing-is-bad